VT7208
/ Vidya Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 04, 2025
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
(clinicaltrials.gov)
- P1/2 | N=100 | Recruiting | Sponsor: Vidya Therapeutics Inc | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Multiple Sclerosis
July 26, 2025
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients
(clinicaltrials.gov)
- P1/2 | N=100 | Not yet recruiting | Sponsor: Vidya Therapeutics Inc
New P1/2 trial • CNS Disorders • Multiple Sclerosis
1 to 2
Of
2
Go to page
1